Michael S D Kormann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8852585/publications.pdf

Version: 2024-02-01

27 papers 2,331 citations

20 h-index 27 g-index

29 all docs

29 docs citations

29 times ranked 3789 citing authors

#	Article	IF	CITATIONS
1	Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology, 2011, 29, 154-157.	17.5	622
2	Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Molecular Therapy - Nucleic Acids, 2018, 12, 530-542.	5.1	178
3	Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling. Gut, 2017, 66, 473-486.	12.1	174
4	Current prospects for mRNA gene delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 484-489.	4.3	169
5	Toll-like receptor heterodimer variants protect from childhood asthma. Journal of Allergy and Clinical Immunology, 2008, 122, 86-92.e8.	2.9	132
6	G-Protein–coupled Receptor Polymorphisms Are Associated with Asthma in a Large German Population. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1358-1362.	5.6	116
7	In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nature Biotechnology, 2015, 33, 584-586.	17.5	113
8	Modified Foxp3 mRNA protects against asthma through an IL-10–dependent mechanism. Journal of Clinical Investigation, 2013, 123, 1216-1228.	8.2	102
9	Chemically modified RNA activated matrices enhance bone regeneration. Journal of Controlled Release, 2015, 218, 22-28.	9.9	91
10	TLR Expression on Neutrophils at the Pulmonary Site of Infection: TLR1/TLR2-Mediated Up-Regulation of TLR5 Expression in Cystic Fibrosis Lung Disease. Journal of Immunology, 2008, 181, 2753-2763.	0.8	86
11	Airway Mucus Obstruction Triggers Macrophage Activation and Matrix Metalloproteinase 12–Dependent Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 709-720.	2.9	76
12	A Comparative Study of the Bone Regenerative Effect of Chemically Modified RNA Encoding BMP-2 or BMP-9. AAPS Journal, 2017, 19, 438-446.	4.4	64
13	Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases. Molecular Therapy, 2019, 27, 803-823.	8.2	60
14	Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Scientific Reports, 2018, 8, 16776.	3.3	59
15	Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors. Molecular and Cellular Pediatrics, 2018, 5, 9.	1.8	49
16	Neutrophils Express Distinct RNA Receptors in a Non-canonical Way. Journal of Biological Chemistry, 2012, 287, 19409-19417.	3.4	47
17	Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin. Scientific Reports, 2020, 10, 10133.	3.3	38
18	A bioactive collagen membrane that enhances bone regeneration. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2019, 107, 1824-1832.	3.4	29

#	Article	lF	CITATIONS
19	<i>CXCR1</i> and <i>CXCR2</i> haplotypes synergistically modulate cystic fibrosis lung disease. European Respiratory Journal, 2012, 39, 1385-1390.	6.7	27
20	Transcriptomic profile of cystic fibrosis patients identifies type I interferon response and ribosomal stalk proteins as potential modifiers of disease severity. PLoS ONE, 2017, 12, e0183526.	2.5	23
21	mRNA-Mediated Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma In Vivo. PLoS ONE, 2016, 11, e0154001.	2.5	20
22	Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies. Molecular and Cellular Pediatrics, 2015, 2, 11.	1.8	19
23	CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases. Advances in Cell and Gene Therapy, 2018, 1, e10.	0.9	13
24	Inhibition of Suicidal Erythrocyte Death by Volasertib. Cellular Physiology and Biochemistry, 2017, 43, 1472-1486.	1.6	10
25	The oral and craniofacial relevance of chemically modified RNA therapeutics. Discovery Medicine, 2016, 21, 35-9.	0.5	6
26	RNA ImmunoGenic Assay: Simple method for detecting immunogenicity of in vitro transcribed mRNA. Advances in Cell and Gene Therapy, 2020, 3, e79.	0.9	2
27	RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of in vitro Transcribed mRNA in Human Whole Blood. Bio-protocol, 2020, 10, e3850.	0.4	2